Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brachytherapy Seed Manufacturers Rally For Discrete OPPS Payment Codes

This article was originally published in The Gray Sheet

Executive Summary

Medicare should accommodate the variability in prices of radioactive sources when transitioning brachytherapy "pass-through" device costs into the ambulatory payment classification (APC) pool, industry reps testified April 5 at CMS' Baltimore "town hall" meeting on the OPPS update for 2003

You may also be interested in...



Multiple Procedure Discount Will Not Apply To APC 225 – OPPS Final Rule

The status indicator for APC 225 (implantation of neurostimulator electrodes) will be changed to "S" for significant procedure, preventing it from receiving a multiple procedure discount, according to the 2003 hospital outpatient prospective payment system final rule

Multiple Procedure Discount Will Not Apply To APC 225 – OPPS Final Rule

The status indicator for APC 225 (implantation of neurostimulator electrodes) will be changed to "S" for significant procedure, preventing it from receiving a multiple procedure discount, according to the 2003 hospital outpatient prospective payment system final rule

Prostate Brachytherapy $5,381 Payment Rate Inadequate – Stakeholders

CMS will need to determine whether the two isotopes used in prostate brachytherapy are cost equivalent before the agency publishes its 2003 hospital outpatient prospective payment system (OPPS) final rule on Nov. 1

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel